Log inSign up
NEJM profile banner
user avatar

NEJM

@NEJM
The New England Journal of Medicine is the world’s leading medical journal and website.
Boston, MA
NEJM.org
Joined March 2009
433
Following
1M
Followers
RepliesArticlesMedia
  • Pinned
    user avatar
    NEJM
    @NEJM
    Aug 6
    Leishmaniasis is a parasitic infection that is transmitted by sand flies and caused by multiple leishmania species, with different species capable of causing cutaneous, visceral, or mucosal forms of the disease. 👉 nej.md/3TnJBKg Cutaneous leishmaniasis usually
    An informative graphic on the pathogenesis, clinical presentation, and treatment of mucosal leishmaniasis caused by Leishmania braziliensis infection. There are maps highlighting affected countries in the Americas. The graphic includes illustrations of cutaneous and mucosal leishmaniasis symptoms and treatment methods, depicting skin lesions and mucosal damage. Treatment options listed involve pharmacological interventions.
  • user avatar
    NEJM
    @NEJM
    48m
    Today’s real-world case on Doctordle is from NEJM! A 91-year-old man develops progressive exertional dyspnea over 8 months with a 35-lb unintentional weight loss. Watch one of NEJM Clinician editors, @ClementLeeMD, play today’s game! Can you guess the diagnosis in five tries
    Image
    00:00
  • user avatar
    NEJM
    @NEJM
    2h
    In a new NEJM Voices blog post, @PaulSaxMD reports on a randomized trial will likely upend influenza treatment guidelines around the world. Learn more and sign up for email alerts: nej.md/4zlJejH
    A quote from an NEJM Voices blog post reads as follows: "Anytime there’s a study that upends common wisdom, we should be grateful that investigators planned and conducted the study, that sites signed up to do it, and that patient participants (or their proxies) agreed to be enrolled. This is the way medical progress happens." The author is Paul E. Sax, M.D. The background color is red and includes the NEJM Voices logo.
  • user avatar
    NEJM
    @NEJM
    3h
    Talquetamab–daratumumab, with or without pomalidomide, led to longer progression-free survival than daratumumab-based standard care in relapsed or refractory myeloma. More than 75% of patients had grade 3 or higher adverse events. Full phase 3 MonumenTAL-3 trial results and
    This image contains an excerpt from the Research Summary "Talquetamab–Daratumumab in Relapsed or Refractory Myeloma" published in the New England Journal of Medicine. It highlights patient details: 864 adults, median age 64, with percentages by sex. A diagram shows a patient with relapsed or refractory multiple myeloma. Three treatment groups are shown: Tal-DP (talquetamab plus daratumumab and pomalidomide) (N=287), Tal-D (talquetamab plus daratumumab) (N=287), and DPd (daratumumab plus pomalidomide and dexamethasone) (N=290). A prompt to read the full Research Summary at NEJM.org sits at the bottom.